Pathstone Family Office’s Immunic IMUX Stock Holding History

Pathstone Family Office’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-186	Closed	-$35K	–	1238
2020 Q3	$35K	Buy	+186	New	+$30.5K	﹤0.01%	406

Other funds holding IMUX

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Pathstone Family Office's IMUX Position: Q4 2020 in Review

Pathstone Family Office sold out of Immunic (IMUX) in Q4 2020, closing a stake of 186 shares — an estimated $35K sold.

Pathstone Family Office first reported a position in IMUX in Q3 2020 and held it in 1 quarter. The position peaked at $35K in Q3 2020. 69 funds tracked by Wall St. Rank hold IMUX as of Q4 2020.

Pathstone Family Office reported no remaining Immunic position as of Q4 2020 after selling out during the quarter.
Pathstone Family Office sold 186 Immunic shares in Q4 2020, an estimated $35K.
Pathstone Family Office first reported a position in Immunic in Q3 2020 and held it in 1 quarter.
Pathstone Family Office's Immunic position peaked at $35K in Q3 2020.
69 funds tracked by Wall St. Rank held Immunic as of Q4 2020.

Based on Pathstone Family Office's 13F filing for Q4 2020, filed 16 Feb 2021.